These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31833634)

  • 1. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN; Dodge JL; Hirose R; Heimbach J; Yao FY; Mehta N
    Liver Transpl; 2020 May; 26(5):662-672. PubMed ID: 31833634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
    Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
    Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
    JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
    Gutin L; Yao F; Dodge JL; Grab J; Mehta N
    JAMA Netw Open; 2019 Aug; 2(8):e1910326. PubMed ID: 31469395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time.
    Sokolich J; Buggs J; LaVere M; Robichaux K; Rogers E; Nyce S; Kumar A; Bowers V
    Am Surg; 2020 Nov; 86(11):1592-1595. PubMed ID: 32812771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
    Lee E; Sarkar M; Dodge J; Kohi M; Mehta N
    Transplantation; 2020 May; 104(5):988-995. PubMed ID: 31577670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.
    Croome KP; Lee DD; Harnois D; Taner CB
    PLoS One; 2017; 12(1):e0170673. PubMed ID: 28122003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
    Alver SK; Lorenz DJ; Marvin MR; Brock GN
    Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.
    Goldberg D; French B; Newcomb C; Liu Q; Sahota G; Wallace AE; Forde KA; Lewis JD; Halpern SD
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1638-1646.e2. PubMed ID: 27374003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
    Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
    Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.